Recent News

• 11.05.2026 - Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
• 11.04.2026 - Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
• 10.30.2026 - Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
• 10.08.2026 - Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
• 07.30.2026 - Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
• 07.21.2026 - Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
• 07.07.2026 - U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
• 06.29.2026 - Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
• 06.13.2026 - Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
• 06.01.2026 - Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

Recent Filings

• 11.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.05.2026 - 8-K Current report
• 11.05.2026 - EX-99.1 EX-99.1
• 10.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.26.2026 - 144 Report of proposed sale of securities
• 10.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.22.2026 - 144 Report of proposed sale of securities
• 10.21.2026 - 144 Report of proposed sale of securities
• 08.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.04.2026 - 144 Report of proposed sale of securities